New Oral Anticoagulants and VTE Management

Slides:

Advertisements

Similar presentations

Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.

Advertisements

Anticoagulation and Thrombosis Management

Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.

EINSTEIN DVT and EINSTEIN PE Pooled Analysis

Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.

Anticoagulation and Thrombosis Management

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,

Dodson Thompson, DO Northlakes Community Clinic Minong, WI.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.

Bleeding complications and management in patients treated with NOACs

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Venous thrombosis , why should I care ?

VTE Guidelines: 2016 update

Clinical Professor in Palliative Medicine

The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.

Ortho Warfarin Dosing Protocol

VTE Management Issues In Malignancy

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

NOACs for Cancer-Associated Thrombosis:

Extended Treatment of VTE: Who is the Right Candidate?

NOACs In Long-term VTE Treatment: A State Of The Art Review

Rome, 15th December 2015 Valeria Maida Medical Affairs

Long-Term Treatment of VTE: Case Studies

When Is Adding Aspirin to NOACs Worth the Risk?

Thrombosis, Cancer, and NOACs

Emergency Management of NOAC Bleeding

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

Timing the First Postoperative Dose of Anticoagulants

Real-World Safety of NOACs: What Do We Know Today?

VTE Treatment Conventional Approach

Learning Objectives Classification of VTE Goals of VTE Treatment.

Timing the First Postoperative Dose of Anticoagulants

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Dos and Don’ts for High-Risk Elderly Patients With AF

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

Anticoagulation and Thrombosis Management

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

Cancer-Associated Thrombosis

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Extraordinary Cases in VTE

How I treat cancer-associated venous thromboembolism

Program Goals Background: Anticoagulation in Patients With VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Disease Burden of VTE Phases of VTE Treatment.

Dipak Patade. NOACs Options for anticoagulation expanding steadily over the past few decades a greater number of agents for prevention and management.

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Antithrombotic Therapy in AF Patients Undergoing PCI

Presentation transcript:

New Oral Anticoagulants and VTE Management

Percentage of Patients at Risk for VTE by Country

Percentage of At-Risk Patients Receiving Recommended Prophylaxis

Recurrent VTE Is a Common Complication

Challenges and Limitations of VKAs

Currently Available Anticoagulants

Conventional 2-Stage Treatment of VTE

New Oral Anticoagulants

Anticoagulant Profiles

Comparisons of Designs of Phase III Acute VTE Trials

RE-COVER Ia and IIb Studies Efficacy and Safety of Dabigatran Compared to Warfarin for 6-Month Treatment of Acute Symptomatic Venous Thromboembolism

RE-COVER I and II Efficacy and Safety Outcomes

Extended VTE Treatment With Dabigatran

ENSTEIN-DVTa/-PEb Studies Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

EINSTEIN-DVT and -PE Trials: Efficacy and Safety Outcomes

EINSTEIN Extension Study

AMPLIFY Study: Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

AMPLIFY Trial: Efficacy and Safety Outcomes

AMPLIFY Extension Study

Hokusai-VTE Study: Comparative Investigation of Edoxaban Versus in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots

Hokusai-VTE Study

Opportunities for NOACs in VTE

Challenges for NOACs

Abbreviations

Abbreviations (cont)